In this one-arm study, histologically or cytologically confirmed advanced NSCLC, uterine malignancies, and soft tissue sarcoma will be enrolled to investigate the efficacy and safety of PD-1 monoclonal antibody SHR-1210 and apatinib, at the same time, peripheral circulating blood tumor cells (CTC) detection and CTC-based PD-L1 antibody immunofluorescence detection will be performed.
Name: PD-1 inhibitor
Name: Apatinib
Description: Evaluated by researchers based on the RECIST 1.1 standard
Measure: Objective remission rate (ORR) Time: 2 yearsDescription: Evaluated by researchers based on the RECIST 1.1 standard
Measure: Progression free survival (PFS) Time: 2 yearsDescription: Evaluated by researchers based on the RECIST 1.1 standard
Measure: Overall survival (OS) Time: 2 yearsDescription: Evaluated by researchers based on the RECIST 1.1 standard
Measure: Duration of response(DOR) Time: 2 yearsDescription: Evaluated by researchers based on the RECIST 1.1 standard
Measure: Disease control rate(DCR) Time: 2 yearsAllocation: N/A
Single Group Assignment
There is one SNP
Inclusion Criteria: 1. Age 18-70 years, both men and women (Uterine cancer limited to women); 2. NSCLC: Pathologically confirmed advanced (IIIB, stage IV) NSCLC with at least 1 measurable lesion that meets the RECIST v1.1 standard without local treatment, of which stage IIIb patients are incapable, unsuitable for surgery or radical radiotherapy, NSCLC patients have failed at least the first-line standard treatment or refused to receive standard treatment, or chemotherapy intolerance, Among them, patients with sensitive gene mutations must fail after TKI treatment (patients who have failed first-line or second-line treatment may participate in this study), Patients with EGFR and ALK mutations must undergo EGFR and ALK inhibitor treatment failure and EGFR T790M mutation negative, for EGFR T790M-positive patients, third-generation EGFR TKI treatment fails. --- T790M ---
Inclusion Criteria: 1. Age 18-70 years, both men and women (Uterine cancer limited to women); 2. NSCLC: Pathologically confirmed advanced (IIIB, stage IV) NSCLC with at least 1 measurable lesion that meets the RECIST v1.1 standard without local treatment, of which stage IIIb patients are incapable, unsuitable for surgery or radical radiotherapy, NSCLC patients have failed at least the first-line standard treatment or refused to receive standard treatment, or chemotherapy intolerance, Among them, patients with sensitive gene mutations must fail after TKI treatment (patients who have failed first-line or second-line treatment may participate in this study), Patients with EGFR and ALK mutations must undergo EGFR and ALK inhibitor treatment failure and EGFR T790M mutation negative, for EGFR T790M-positive patients, third-generation EGFR TKI treatment fails. --- T790M --- --- T790M ---
To the safety of the subject, or the collection of information and samples; Inclusion Criteria: 1. Age 18-70 years, both men and women (Uterine cancer limited to women); 2. NSCLC: Pathologically confirmed advanced (IIIB, stage IV) NSCLC with at least 1 measurable lesion that meets the RECIST v1.1 standard without local treatment, of which stage IIIb patients are incapable, unsuitable for surgery or radical radiotherapy, NSCLC patients have failed at least the first-line standard treatment or refused to receive standard treatment, or chemotherapy intolerance, Among them, patients with sensitive gene mutations must fail after TKI treatment (patients who have failed first-line or second-line treatment may participate in this study), Patients with EGFR and ALK mutations must undergo EGFR and ALK inhibitor treatment failure and EGFR T790M mutation negative, for EGFR T790M-positive patients, third-generation EGFR TKI treatment fails. --- T790M ---
To the safety of the subject, or the collection of information and samples; Inclusion Criteria: 1. Age 18-70 years, both men and women (Uterine cancer limited to women); 2. NSCLC: Pathologically confirmed advanced (IIIB, stage IV) NSCLC with at least 1 measurable lesion that meets the RECIST v1.1 standard without local treatment, of which stage IIIb patients are incapable, unsuitable for surgery or radical radiotherapy, NSCLC patients have failed at least the first-line standard treatment or refused to receive standard treatment, or chemotherapy intolerance, Among them, patients with sensitive gene mutations must fail after TKI treatment (patients who have failed first-line or second-line treatment may participate in this study), Patients with EGFR and ALK mutations must undergo EGFR and ALK inhibitor treatment failure and EGFR T790M mutation negative, for EGFR T790M-positive patients, third-generation EGFR TKI treatment fails. --- T790M --- --- T790M ---